On Monday, Shares of Microsoft Corporation (NASDAQ:MSFT), gained 0.79% to $47.23.
Microsoft Corporation, declared the recipients of the 2015 Microsoft Supplier Program (MSP) Excellence Awards. The MSP Excellence Awards recognize superior performance, exemplary service and innovation by suppliers that demonstrate what it means to be a preferred supplier at Microsoft. The purpose of the MSP is to build long-term relationships with a select group of planned suppliers that create long-term value for Microsoft.
Winners of the 2015 MSP Excellence Awards were nominated by employees of Microsoft in various business units, MSP suppliers and Microsoft Procurement Professionals. An extensive panel of Microsoft employees and external judges selects all final awardees.
Award winners were based on excellence in a number of areas, counting quality, value, service and innovation. Winners were declared during the 13th Annual MSP Summit on Microsoft’s main corporate campus in Redmond, Wash.
Microsoft Corporation develops, licenses, markets, and supports software, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system.
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), declined -1.32% to $2.25, during its last trading session.
Advanced Micro Devices, declared that Jim Anderson (43) has joined the company as senior vice president and general manager of AMD’s Computing and Graphics (CG) business group, reporting to President and CEO Dr. Lisa Su. Anderson will be responsible for managing all aspects of strategy, business administration, engineering, and sales for AMD’s computing and graphics products and solutions.
Anderson joins AMD from Intel Corporation where he accomplished the acquisition and successful integration of the Axxia processor business from Avago Technologies to Intel. Anderson spent the last decade at Avago Technologies and LSI Corporation in a variety of leadership positions spanning planned planning, marketing, engineering, sales, and general administration. Preceding to LSI, Anderson held planned planning roles at Intel Corporation for mobile/laptop and server processors in addition to serving as a microprocessor architect.
Throughout his career, Anderson has consistently demonstrated an ability to transform businesses to achieve noteworthy revenue growth based on developing a holistic strategy across hardware and software engineering, marketing, product administration, and customer service functions.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
At the end of Monday’s trade, Shares of Exelixis, Inc. (NASDAQ:EXEL), gained 9.21% to $3.44.
Exelixis, declared positive results from a two-stage phase 2 investigator-sponsored trial (IST) evaluating cabozantinib in patients with advanced RET-rearranged lung cancers. Data were stated for the first stage, which enrolled 16 patients. The objective response rate (ORR) was 38% (6/16), with a median duration of response of 8 months. Although the trial is still accruing, it has already met its primary endpoint, surpassing the predefined targeted number of five objective responses. Alexander Drilon, M.D. of New York’s Memorial Sloan Kettering Cancer Center (MSKCC) will present the data (Abstract #8007) recently during an oral abstract session at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
Study Design
This single-institution, open-label phase 2 trial evaluates cabozantinib in patients with advanced RET-rearranged NSCLC, counting the KIF5B-RET fusion, the most common rearrangement. Eligible patients must have stage IV lung cancer (with RET rearrangement confirmed by break apart fluorescence in situ hybridization and/or next generation sequencing), Karnofsky Performance Status greater than 70 percent, and measurable disease per RECIST 1.1. Patients receive 60 mg daily cabozantinib in 28-day cycles until disease progression or unacceptable toxicity.
The trial is designed to enroll a maximum of 25 patients in two stages. The first stage of the trial, the subject of today’s data presentation, enrolled 16 patients, and one partial response was required to expand the trial into its second stage that will enroll an additional nine patients.
The primary endpoint of the trial is ORR, with five partial responses (PRs) required to meet the endpoint. Secondary endpoints comprise response rate at 12 weeks, progression-free survival (PFS), overall survival (OS), and toxicity.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Finally, Ignyta, Inc. (NASDAQ:RXDX), ended its last trade with 65.92% surge, and closed at $14.90, hitting its highest level.
Ignyta, declared that interim results from the company’s two Phase 1 clinical trials of entrectinib were presented in poster presentations, counting a poster talk aboution, at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Entrectinib is the company’s proprietary oral tyrosine kinase inhibitor targeting tumors that harbor activating alterations to NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1 or ALK.
The clinical trials comprised of the ALKA-372-001 study and the STARTRK-1 study, which is the first of the “Studies Targeting Alterations Responsive to Targeted Receptor Kinase” inhibition. Both trials were designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, in addition to preliminary anti-cancer activity, of single agent entrectinib in patients with solid tumors with the relevant molecular alterations: NTRK1 (encoding TrkA), ROS1 or ALK for ALKA-372-001 and NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1 or ALK for STARTRK-1.
Ignyta, Inc., a precision oncology biotechnology company, engages in discovering or acquiring, developing, and commercializing new drugs for cancer patients. Its products pipeline comprises of entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related and protein kinase.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
